Gentium Receives Marketing Authorization for Defitelio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gentium Receives Marketing Authorization for Defitelio



Gentium S.p.A. has reported that the European Commission has granted a marketing authorization for Defitelio (R)(defibrotide) for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation therapy. Defitelio (R) is the first approved treatment in the European Union for this condition. This authorization is the formal endorsement of the positive opinion received from the EMA Committee for Human Medicinal Product on July 26, 2013. Gentium intends to begin commercialization of Defitelio (R) in the EU in December 2013.

Source: Gentium

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here